vs

Side-by-side financial comparison of MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) and Safehold Inc. (SAFE). Click either name above to swap in a different company.

Safehold Inc. is the larger business by last-quarter revenue ($97.9M vs $49.9M, roughly 2.0× MARAVAI LIFESCIENCES HOLDINGS, INC.). Safehold Inc. runs the higher net margin — 28.5% vs -71.6%, a 100.0% gap on every dollar of revenue. On growth, Safehold Inc. posted the faster year-over-year revenue change (6.5% vs -11.8%). Over the past eight quarters, Safehold Inc.'s revenue compounded faster (2.5% CAGR vs -11.9%).

Maravai LifeSciences Holdings is a global life sciences firm developing critical reagents, diagnostic products, and tech solutions to support biopharma research, drug development, clinical diagnostics, and cell/gene therapy manufacturing. It serves biotech, pharma, research bodies and labs worldwide across three core segments.

SAFE Investment Company Limited is a Chinese sovereign wealth fund based in Hong Kong.

MRVI vs SAFE — Head-to-Head

Bigger by revenue
SAFE
SAFE
2.0× larger
SAFE
$97.9M
$49.9M
MRVI
Growing faster (revenue YoY)
SAFE
SAFE
+18.4% gap
SAFE
6.5%
-11.8%
MRVI
Higher net margin
SAFE
SAFE
100.0% more per $
SAFE
28.5%
-71.6%
MRVI
Faster 2-yr revenue CAGR
SAFE
SAFE
Annualised
SAFE
2.5%
-11.9%
MRVI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MRVI
MRVI
SAFE
SAFE
Revenue
$49.9M
$97.9M
Net Profit
$-35.7M
$27.9M
Gross Margin
25.8%
98.6%
Operating Margin
-117.9%
27.4%
Net Margin
-71.6%
28.5%
Revenue YoY
-11.8%
6.5%
Net Profit YoY
-37.7%
7.1%
EPS (diluted)
$-0.24
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRVI
MRVI
SAFE
SAFE
Q4 25
$49.9M
$97.9M
Q3 25
$41.6M
$96.2M
Q2 25
$47.4M
$93.8M
Q1 25
$46.9M
$97.7M
Q4 24
$56.6M
$91.9M
Q3 24
$69.0M
$90.7M
Q2 24
$69.4M
$89.9M
Q1 24
$64.2M
$93.2M
Net Profit
MRVI
MRVI
SAFE
SAFE
Q4 25
$-35.7M
$27.9M
Q3 25
$-25.6M
$29.3M
Q2 25
$-39.6M
$27.9M
Q1 25
$-29.9M
$29.4M
Q4 24
$-25.9M
$26.0M
Q3 24
$-97.1M
$19.3M
Q2 24
$-9.8M
$29.7M
Q1 24
$-12.1M
$30.7M
Gross Margin
MRVI
MRVI
SAFE
SAFE
Q4 25
25.8%
98.6%
Q3 25
13.6%
98.5%
Q2 25
16.4%
99.1%
Q1 25
16.5%
98.8%
Q4 24
34.3%
98.8%
Q3 24
46.7%
98.8%
Q2 24
44.4%
98.8%
Q1 24
40.3%
98.8%
Operating Margin
MRVI
MRVI
SAFE
SAFE
Q4 25
-117.9%
27.4%
Q3 25
-98.6%
25.9%
Q2 25
-139.8%
25.5%
Q1 25
-104.9%
25.9%
Q4 24
-66.7%
24.6%
Q3 24
-239.9%
17.5%
Q2 24
-19.4%
26.7%
Q1 24
-29.4%
26.4%
Net Margin
MRVI
MRVI
SAFE
SAFE
Q4 25
-71.6%
28.5%
Q3 25
-61.4%
30.5%
Q2 25
-83.5%
29.8%
Q1 25
-63.9%
30.1%
Q4 24
-45.8%
28.3%
Q3 24
-140.6%
21.3%
Q2 24
-14.1%
33.0%
Q1 24
-18.8%
33.0%
EPS (diluted)
MRVI
MRVI
SAFE
SAFE
Q4 25
$-0.24
$0.38
Q3 25
$-0.18
$0.41
Q2 25
$-0.27
$0.39
Q1 25
$-0.21
$0.41
Q4 24
$-0.21
$0.36
Q3 24
$-0.68
$0.27
Q2 24
$-0.07
$0.42
Q1 24
$-0.09
$0.43

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRVI
MRVI
SAFE
SAFE
Cash + ST InvestmentsLiquidity on hand
$216.9M
$21.7M
Total DebtLower is stronger
$291.8M
$4.6B
Stockholders' EquityBook value
$212.4M
$2.4B
Total Assets
$770.6M
$7.2B
Debt / EquityLower = less leverage
1.37×
1.90×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRVI
MRVI
SAFE
SAFE
Q4 25
$216.9M
$21.7M
Q3 25
$243.6M
$12.1M
Q2 25
$269.9M
$13.9M
Q1 25
$285.1M
$17.3M
Q4 24
$322.4M
$8.3M
Q3 24
$578.2M
$15.6M
Q2 24
$573.2M
$13.4M
Q1 24
$561.7M
$11.3M
Total Debt
MRVI
MRVI
SAFE
SAFE
Q4 25
$291.8M
$4.6B
Q3 25
$292.8M
$4.5B
Q2 25
$293.9M
$4.4B
Q1 25
$294.9M
$4.3B
Q4 24
$295.9M
$4.3B
Q3 24
$521.7M
$4.3B
Q2 24
$522.5M
$4.2B
Q1 24
$523.3M
$4.1B
Stockholders' Equity
MRVI
MRVI
SAFE
SAFE
Q4 25
$212.4M
$2.4B
Q3 25
$245.4M
$2.4B
Q2 25
$265.9M
$2.4B
Q1 25
$300.6M
$2.4B
Q4 24
$325.3M
$2.3B
Q3 24
$344.9M
$2.3B
Q2 24
$434.7M
$2.3B
Q1 24
$410.7M
$2.3B
Total Assets
MRVI
MRVI
SAFE
SAFE
Q4 25
$770.6M
$7.2B
Q3 25
$849.2M
$7.1B
Q2 25
$897.0M
$7.1B
Q1 25
$959.8M
$6.9B
Q4 24
$1.0B
$6.9B
Q3 24
$1.3B
$6.8B
Q2 24
$1.4B
$6.8B
Q1 24
$1.4B
$6.7B
Debt / Equity
MRVI
MRVI
SAFE
SAFE
Q4 25
1.37×
1.90×
Q3 25
1.19×
1.89×
Q2 25
1.11×
1.87×
Q1 25
0.98×
1.85×
Q4 24
0.91×
1.84×
Q3 24
1.51×
1.88×
Q2 24
1.20×
1.81×
Q1 24
1.27×
1.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRVI
MRVI
SAFE
SAFE
Operating Cash FlowLast quarter
$-22.8M
$47.8M
Free Cash FlowOCF − Capex
$-24.9M
FCF MarginFCF / Revenue
-49.9%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
1.72×
TTM Free Cash FlowTrailing 4 quarters
$-70.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRVI
MRVI
SAFE
SAFE
Q4 25
$-22.8M
$47.8M
Q3 25
$-15.2M
$-1.4M
Q2 25
$-10.3M
$28.0M
Q1 25
$-9.4M
$8.9M
Q4 24
$-14.6M
$37.9M
Q3 24
$13.1M
$8.3M
Q2 24
$17.4M
$24.8M
Q1 24
$-8.5M
$-3.1M
Free Cash Flow
MRVI
MRVI
SAFE
SAFE
Q4 25
$-24.9M
Q3 25
$-18.1M
Q2 25
$-13.1M
Q1 25
$-14.6M
Q4 24
$-20.5M
Q3 24
$4.5M
Q2 24
$7.9M
Q1 24
$-14.1M
FCF Margin
MRVI
MRVI
SAFE
SAFE
Q4 25
-49.9%
Q3 25
-43.4%
Q2 25
-27.7%
Q1 25
-31.2%
Q4 24
-36.2%
Q3 24
6.6%
Q2 24
11.4%
Q1 24
-22.0%
Capex Intensity
MRVI
MRVI
SAFE
SAFE
Q4 25
4.2%
Q3 25
7.0%
Q2 25
6.1%
Q1 25
11.2%
Q4 24
10.3%
Q3 24
12.4%
Q2 24
13.8%
Q1 24
8.8%
Cash Conversion
MRVI
MRVI
SAFE
SAFE
Q4 25
1.72×
Q3 25
-0.05×
Q2 25
1.00×
Q1 25
0.30×
Q4 24
1.45×
Q3 24
0.43×
Q2 24
0.83×
Q1 24
-0.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRVI
MRVI

Cygnus Segment$27.2M54%
Other$18.4M37%
Shipping And Handling$4.3M9%

SAFE
SAFE

Equity Method Investment Nonconsolidated Investee Or Group Of Investees$60.3M62%
Other$33.7M34%
Stabilized Properties$3.8M4%

Related Comparisons